Dieci, M V <br/><br/>
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  10 2016 
 - 1867-73 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdw262  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Biopsy, Large-Core Needle<br/>Breast Neoplasms--drug therapy<br/>Female<br/>Humans<br/>Lapatinib<br/>Lymphocytes, Tumor-Infiltrating--immunology<br/>Microarray Analysis<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Prognosis<br/>Quinazolines--administration & dosage<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Receptors, Estrogen--genetics<br/>Trastuzumab--administration & dosage